Pfizer Inc.
Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies. Pfizer’s GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.
The landscape of treatment for inflammatory skin conditions, including Atopic Dermatitis and Alopecia Areata is advancing, with more evidence and therapeutic options available to the community
. Through this RFP it is our intent to support educational projects that focus on addressing knowledge and practice gaps specific to the recognition, diagnosis, treatment, and overall care management of atopic dermatitis (AD) and/or Alopecia Areata (AA). Projects that will be considered for Pfizer support should focus on increasing the knowledge and understanding of: 1) the pathophysiology of AA and/or AD with specific focus on immunologic pathways 2) the epidemiology of the disease(s), including an understanding of the risk factors for the development of the disease(s), comorbidities, and safety events relevant to systemic therapies 3) understanding the clinical manifestation of AD/AA, including a holistic review of the burden of disease (e.g. psychosocial burden and associated autoimmune disorders) 4) new advances in the treatment pathways of AA and/or AD 5) mechanism of action of treatments in AA and/or AD 6) the benefit:risk profile of AA and/or AD treatments.
Grant Application due date: October 4, 2021